viewMaxCyte Inc

Maxcyte reports 30% revenue growth as key programmes advance through clinical studies

Proactive research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) results for the year to December 2019.

Ulker says the firm delivered a consensus-beating 30% uplift in full-year 2019 revenues to US$21.6mln - underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies and by a 25% five-year revenue compound annualised growth rate (CAGR).


Click here to read the latest research update on MaxCyte : Milestones a key contributor to 30% top line growth

Quick facts: MaxCyte Inc

Price: 412 GBX

Market: AIM
Market Cap: £317.9 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...


MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 08/18/2020

2 min read